Designing production facilities of the future
30th July 2019 | 10:00AM EST | Geoffry Hodge, Chief Technical Officer at Unum Therapeutics and Gary M. Pigeau, Ph.D., Director - Centre for Advanced Therapeutic Cell Technologies at GE Healthcare |BOOK FREE SEAT
- How can facilities be produced to meet the potential demand of cell and viral vectors
- What needs to change and what innovations are being made
Presented by Geoffry Hodge, Chief Technical Officer at Unum Therapeutics
Geoff is responsible for leading the development and execution of Unum’s CMC and technical operations, including process and analytical development, manufacturing, and quality, for the company’s proprietary antibody-coupled T-cell receptor (ACTR) therapies. He has over 25 years of experience in the biotechnology industry, providing bioprocessing technical solutions for companies including Millennium Pharmaceuticals, Genetics Institute (Wyeth), and Alpha-Beta Technology. Prior to joining Unum, Geoff was a co-founder of Xcellerex, inventor on several of Xcellerex’s foundational single-use technology patents, and an operations leader at Xcellerex. He holds an M.S. from WPI and bachelor’s degree from Colgate.
Followed by Gary M. Pigeau, Ph.D., Director – Centre for Advanced Therapeutic Cell Technologies at GE Healthcare
Gary Pigeau received his Ph.D. in Biotechnology from Brock University in St. Catharines, Ontario. He completed a postdoctoral fellowship at the University of Alberta with a visiting scientist appointment at the University of Oxford. Gary moved to private industry in 2008, where his research group focused on process development and scale-up of a proprietary bioprocess technology. He then moved to commercial, large-scale biomanufacturing in 2013. Gary joined GE Healthcare and the Centre for Advanced Therapeutic Cell Technologies (CATCT) @ CCRM in 2016 and led the pluripotent stem cell process development, scale-up and manufacturing efforts. Today, Gary is the GEHC Director of the CATCT delivering on customer-focused fee for service process, media and assay development projects, development of new products for GE Healthcare and internal technology development projects to continue to develop and grow capabilities within the group.
Sponsored by GE Healthcare Life Sciences
At GE Healthcare’s Life Sciences, we accelerate precision medicine by helping researchers, pharmaceutical companies, and clinicians discover and make new medicines and therapies. We provide expertise, technology, and services for the life sciences industry. This includes contrast agent manufacturing for diagnostic imaging, basic cell and protein research, and technologies for large-scale vaccine, biologic, and cell therapy manufacturing.
Cell therapy is emerging as a treatment for challenging diseases, including cancer. Our Cell Therapy business provides the tools, technology, and processes to enable customers from pharmaceutical manufacturing as part of our Cell Processing segment, to clinicians and technicians in our Cell Banking and Point of Care segments. We are investing in the field for the long-term, and partnering with pharma, biotech, and clinical researchers. GE brings expertise in quality, global distribution, R&D, and regulatory that will transform cell therapy from small-scale treatment to a globally accessible personalized medicine.